Posters
Corneal biomechanical properties in Egyptian glaucomatous patients
Poster Details
First Author: A. Gab-Alla EGYPT
Co Author(s): M. Shahin W. Ghowbashy M. Ammar
Abstract Details
Purpose:
To describe corneal biomechanics profile in Egyptian glaucomatous patients, and to compare between corneal biomechanics of normal individuals and glaucoma patients.
Setting:
Ophthalmology Department, Suez Canal University Hospital, Ismailia, Egypt and Cortoba eye center.
Methods:
The study included Group (A) of 41 eyes receiving medical treatment for glaucoma (diagnosed by elevated IOP, gonioscopy, decreased RNFL by Stratus OCT and searched for visual field Loss using Humphery field analyzer, Carl Zeiss Meditec, Germany). Group (B) of 41 healthy eyes of individuals with matching age and sex. Subjects with previous ocular surgeries or any coexisting ocular diseases such as corneal pathology were excluded. Examination included UCVA, BCVA, refraction, slit lamp biomicroscopy and dilated fundus examination. Corneal biomechanics parameters: CH, CRF, IOPg, IOPcc as well as CCT were measured using Ocular Response Analyzer by Reichert, NY.
Results:
The mean age of group A was 49.7 yrs. ± 14.8 and 46 yrs. ± 13.7 in group B, with males, constituted 56.5% of group A and 44.4% of group B. Although there was no significant difference between CCT in both groups, Corneal hysteresis was significantly lower in glaucomatous eyes with a mean of 7.7±1.3 in comparison to 9.4± 1.5 in normal eyes.(p=0.001). Conversely, corneal resistance factor was found to be significantly higher in group A with a mean of 11.2± 2.3 compared to 9.7± 1.5 in group B (p=0.001). The IOPcc was found to be significantly higher than IOPg in both groups, and this was remarkable in glaucomatous eyes.
Conclusions:
Glaucomatous eyes tend to have lower values of corneal hysteresis and higher values of corneal resistance factor when compared to healthy eyes. This seems to be independent of the central corneal thickness. IOPcc measurement should be considered in the evaluation and follow-up of glaucomatous eyes.
Financial Disclosure:
NONE